

**Disclosure:** This table is for informational purposes only. Primary references and full prescribing information should be consulted for additional research.

Name	Regimen	Reference
<b>Single agents</b>		
Capecitabine	1,250 mg/m <sup>2</sup> PO bid, days 1–14, followed by 7 days rest <i>Repeat every 3 weeks</i>	Hoff et al. <i>J Clin Oncol.</i> 2001;19:2282-2292.
Irinotecan	125 mg/m <sup>2</sup> over 90 minutes, days 1, 8, 15, 22 <i>Repeat every 6 weeks</i>	Saltz et al. <i>N Engl J Med.</i> 2000;343:905-914.
Irinotecan	300 or 350 mg/m <sup>2</sup> IV over 90 minutes, day 1 <i>Repeat every 3 weeks</i>	Cunningham et al. <i>Lancet.</i> 1998;352:1413-1418.
Cetuximab	400 mg/m <sup>2</sup> IV over 2 hours week 1 followed by 250 mg/m <sup>2</sup> IV over 1 hour weekly	Saltz et al. <i>J Clin Oncol.</i> 2004;22:1201-1208.
<b>Combination regimens</b>		
5-FU/LV Roswell Park regimen	<b>LV</b> 500 mg/m <sup>2</sup> IV over 2 hours, days 1, 8, 15, 22, 29, 36 <b>5-FU</b> 600 mg/m <sup>2</sup> IV bolus 1 hour after start of LV, days 1, 8, 15, 22, 29, 36 <i>Repeat every 8 weeks</i>	Petrelli et al. <i>J Clin Oncol.</i> 1989;7:1419-1426.
5-FU/LV Mayo regimen	<b>LV</b> 20 mg/m <sup>2</sup> IV bolus, days 1–5 <b>5-FU</b> 370 mg/m <sup>2</sup> IV bolus 1 hour after start of LV, days 1–5 <i>Repeat cycle at 4 and 8 weeks and every 5 weeks thereafter</i>	Poon et al. <i>J Clin Oncol.</i> 1989;7:1407-1418.
5-FU/LV de Gramont regimen (LV5FU2)	<b>LV</b> 200 mg/m <sup>2</sup> IV over 2 hours, days 1 and 2 <b>5-FU</b> 400 mg/m <sup>2</sup> IV bolus, then 600 mg/m <sup>2</sup> IV over 22 hours, days 1 and 2 <i>Repeat every 2 weeks</i>	de Gramont et al. <i>J Clin Oncol.</i> 1997;15:808-815. de Gramont et al. <i>J Clin Oncol.</i> 2000;18:2938-2947.
IFL Saltz regimen	<b>Irinotecan</b> 125 mg/m <sup>2</sup> IV over 90 minutes, days 1, 8, 15, 22 <b>LV</b> 20 mg/m <sup>2</sup> IV bolus, days 1, 8, 15, 22 <b>5-FU</b> 500 mg/m <sup>2</sup> IV bolus, days 1, 8, 15, 22 <i>Repeat every 6 weeks</i>	Saltz et al. <i>N Engl J Med.</i> 2000;343:905-914.
Irinotecan + 5-FU/LV Douillard regimen	<b>Irinotecan</b> 180 mg/m <sup>2</sup> over 2 hours, day 1 <b>LV</b> 200 mg/m <sup>2</sup> IV over 2 hours prior to 5-FU, days 1 and 2 <b>5-FU</b> 400 mg/m <sup>2</sup> IV bolus, then 600 mg/m <sup>2</sup> continuous infusion over 22 hours, days 1 and 2 <i>Repeat every 2 weeks</i>	Douillard et al. <i>Lancet.</i> 2000;355:1041-1047.
FOLFIRI	<b>Irinotecan</b> 180 mg/m <sup>2</sup> over 90 minutes, day 1 <b>LV</b> 200 mg/m <sup>2</sup> over 2-hour infusion during irinotecan <b>5-FU</b> bolus 400 mg/m <sup>2</sup> , then 2.4–3 g/m <sup>2</sup> continuous infusion over 46 hours, days 1 and 2 <i>Repeat every 2 weeks</i>	André et al. <i>Eur J Cancer.</i> 1999;35:1343-1347. Tournigand et al. <i>J Clin Oncol.</i> 2004;23:229-237.
Caplri	<b>Capecitabine</b> 1,000 mg/m <sup>2</sup> PO bid, days 1–14 <b>Irinotecan</b> 100 mg/m <sup>2</sup> , days 1 and 8 <i>Repeat every 22 days</i>	Grothey et al. <i>Proc Am Soc Clin Oncol.</i> 2003;22:255. Abstract 1022.
FOLFOX4	<b>Oxaliplatin</b> 85 mg/m <sup>2</sup> IV over 2 hours, day 1 <b>LV</b> 200 mg/m <sup>2</sup> IV over 2 hours, days 1 and 2 <b>5-FU</b> 400 mg/m <sup>2</sup> IV bolus, then 600 mg/m <sup>2</sup> IV over 22 hours, days 1 and 2 <i>Repeat every 2 weeks</i>	de Gramont et al. <i>J Clin Oncol.</i> 2000;18:2938-2947. Rothenberg et al. <i>J Clin Oncol.</i> 2003;21:2059-2069.
FOLFOX6	<b>Oxaliplatin</b> 100 mg/m <sup>2</sup> IV over 2 hours, day 1 <b>LV</b> 200 mg/m <sup>2</sup> IV over 2 hours, day 1 <b>5-FU</b> 400 mg/m <sup>2</sup> IV bolus, then 2.4–3 g/m <sup>2</sup> over 46 hours, continuous infusion <i>Repeat every 2 weeks</i>	Maindault-Goebel et al. <i>Eur J Cancer.</i> 1999;35:1338-1342. Tournigand et al. <i>J Clin Oncol.</i> 2004;23:229-237.
mFOLFOX6	<b>Oxaliplatin</b> 85 mg/m <sup>2</sup> IV over 2 hours, day 1 <b>LV</b> 175 mg/m <sup>2</sup> IV over 2 hours, day 1 <b>5-FU</b> 400 mg/m <sup>2</sup> IV bolus, then 2.4–3 g/m <sup>2</sup> over 46 hours, continuous infusion <i>Repeat every 2 weeks</i>	Cheeseman et al. <i>Br J Cancer.</i> 2002;87:393-399.

Name	Regimen	Reference
FOLFOX7	<b>Oxaliplatin</b> 130 mg/m <sup>2</sup> IV over 2 hours, day 1 <b>LV</b> 400 mg/m <sup>2</sup> IV over 2 hours <b>5-FU</b> 2,400 mg/m <sup>2</sup> IV over 46 hours, continuous infusion <i>Repeat every 2 weeks for 6 cycles</i>	André et al. <i>Proc Am Soc Clin Oncol.</i> 2003;22:253. Abstract 1016.
FLOX	<b>Oxaliplatin</b> 85 mg/m <sup>2</sup> IV over 2 hours, days 1, 15, 29 <b>LV</b> 500 mg/m <sup>2</sup> IV over 2 hours, days 1, 8, 15, 22, 29, 36 <b>5-FU</b> 500 mg/m <sup>2</sup> IV bolus <u>1 hour after start of LV</u> , days 1, 8, 15, 22, 29, 36 <i>Repeat every 8 weeks for 3 cycles</i>	Smith et al. <i>Proc Am Soc Clin Oncol.</i> 2003;22:294. Abstract 1181.
FUFOX	<b>Oxaliplatin</b> 60 mg/m <sup>2</sup> IV over 2 hours, days 1, 8, 15, 22 <b>LV</b> 500 mg/m <sup>2</sup> IV over 2 hours, days 1, 8, 15, 22 <b>5-FU</b> 2.6 g/m <sup>2</sup> IV over 24 hours, continuous infusion, days 1, 8, 15, 22 <i>Repeat every 36 days</i>	Moehler et al. <i>Z Gastroenterol.</i> 2002;40:957-964.
bFOL	<b>Oxaliplatin</b> 85 mg/m <sup>2</sup> IV over 2 hours, every 2 weeks <b>LV</b> 20 mg/m <sup>2</sup> IV over 10–20 minutes, days 1, 8, 15 <b>5-FU</b> 500 mg/m <sup>2</sup> IV bolus, days 1, 8, 15 <i>Repeat every 28 days</i>	Hochester et al. <i>J Clin Oncol.</i> 2003;21:2703-2707.
FOLFOX 4 + Bevacizumab	<b>Oxaliplatin</b> 85 mg/m <sup>2</sup> IV over 2 hours, day 1 <b>LV</b> 200 mg/m <sup>2</sup> IV over 2 hours, days 1 and 2 <b>5-FU</b> 400 mg/m <sup>2</sup> IV bolus, then 600 mg/m <sup>2</sup> IV over 22 hours, days 1 and 2 <b>Bevacizumab</b> 10 mg/kg IV over 90 minutes,* day 1 <i>Repeat every 2 weeks</i>	Benson et al. <i>Proc Am Soc Clin Oncol.</i> 2003;22:243. Abstract 975.
FOLFOX4 + Cetuximab	<b>Oxaliplatin</b> 85 mg/m <sup>2</sup> IV over 2 hours, day 1 <b>LV</b> 200 mg/m <sup>2</sup> IV over 2 hours, days 1 and 2 <b>5-FU</b> 400 mg/m <sup>2</sup> IV bolus, then 600 mg/m <sup>2</sup> IV over 22 hours, days 1 and 2 <i>Repeat every 2 weeks</i> <b>Cetuximab</b> 400 mg/m <sup>2</sup> IV over 2 hours week 1 followed by 250 mg/m <sup>2</sup> IV over 60 minutes weekly	Tabernero et al. <i>Proc Am Soc Clin Oncol.</i> 2004;23:248. Abstract 3512.
XELOX	<b>Oxaliplatin</b> 130 mg/m <sup>2</sup> IV over 2 hours, day 1 <b>Capecitabine</b> 1000 mg/m <sup>2</sup> PO bid, evening day 1–morning day 15 <i>Repeat every 3 weeks</i>	Van Cutsem et al. <i>Proc Am Soc Clin Oncol.</i> 2003;22:255. Abstract 1023.
XELIRI	<b>Irinotecan</b> 250 mg/m <sup>2</sup> IV, day 1 <b>Capecitabine</b> 1,000 mg/m <sup>2</sup> PO bid, evening day 1–morning day 15 <i>Repeat every 3 weeks</i>	Patt et al. <i>Proc Am Soc Clin Oncol.</i> 2004;23:271. Abstract 3602.
CapOx	<b>Oxaliplatin</b> 70 mg/m <sup>2</sup> IV, days 1 and 8 <b>Capecitabine</b> 1,000 mg/m <sup>2</sup> PO bid, days 1–14 <i>Repeat every 22 days</i>	Grothey et al. <i>Proc Am Soc Clin Oncol.</i> 2003;22:255. Abstract 1022.
IROX	<b>Irinotecan</b> 200 mg/m <sup>2</sup> IV over 90 minutes, day 1 <b>Oxaliplatin</b> 85 mg/m <sup>2</sup> IV over 2 hours, day 1 <i>Repeat every 3 weeks</i>	Goldberg et al. <i>J Clin Oncol.</i> 2004;22:23-30.
IFL + Bevacizumab	<b>Irinotecan</b> 125 mg/m <sup>2</sup> IV over 90 minutes, days 1, 8, 15, 22 <b>LV</b> 20 mg/m <sup>2</sup> IV, days 1, 8, 15, 22 <b>5-FU</b> 500 mg/m <sup>2</sup> IV, days 1, 8, 15, 22 <i>Repeat every 6 weeks</i> <b>Bevacizumab</b> 5 mg/kg IV over 90 minutes* following chemotherapy, day 1 <i>Repeat every 2 weeks</i>	Hurwitz et al. <i>N Engl J Med.</i> 2004;350:2335-2342.

CRC = colorectal cancer; 5-FU = 5-fluorouracil; LV = leucovorin.

\*If first infusion is well tolerated, subsequent infusions may be administered over 60 minutes and then 30 minutes.